Varian Medical Systems (VAR) plans to demonstrate a more precise procedure for computing the dosimetry for cancer treatment at the annual convention of the American Association of Physicists in Medicine (AAPM) to be held in Philadelphia during July 18 to 22, 2010. Medical experts have studied the dosimetric computation abilities of Varian’s Acuros BV, since its launch in 2009, and some may present their findings at AAPM meeting.
Acuros BV permits medical providers to quickly and precisely compute the dosage required for brachytherapy radiotherapy treatment. It is expected that Acuros BV, by improving the computation of dosage, will empower practitioners with enhanced decision-making skills.
Previously, clinicians calculated dosage limits for brachytherapy with an assumption that the sources are engulfed by water. However, a patient’s body, actually, consists of a multitude of matter such as tissue, bone and air. Formerly, clinicians accounted for this divergence by utilizing Monte Carlo computation techniques, available as a research capability. Finally, Acuros BV is now able to empower clinicians in routine clinical brachytherapy.
The algorithm for calculation of dosage, which is integral to Varian’s Acuros BV, will operate at a speed that compares favorably with Monte Carlo software packages. Further, Acuros BV will generate high dose rate brachytherapy dose distributions with greater precision than feasible under older systems.
Varian Medical Systems manufactures and sells both medical devices and software for treating cancer and medical conditions associated with radiosurgery and radiotherapy. It is also a leading provider of digital detectors for X-ray imaging in different applications. In addition, the company caters to X-ray imaging requirement for cargo screening and industrial inspection.
We currently have a Neutral rating on Varian.
Acuros BV permits medical providers to quickly and precisely compute the dosage required for brachytherapy radiotherapy treatment. It is expected that Acuros BV, by improving the computation of dosage, will empower practitioners with enhanced decision-making skills.
Previously, clinicians calculated dosage limits for brachytherapy with an assumption that the sources are engulfed by water. However, a patient’s body, actually, consists of a multitude of matter such as tissue, bone and air. Formerly, clinicians accounted for this divergence by utilizing Monte Carlo computation techniques, available as a research capability. Finally, Acuros BV is now able to empower clinicians in routine clinical brachytherapy.
The algorithm for calculation of dosage, which is integral to Varian’s Acuros BV, will operate at a speed that compares favorably with Monte Carlo software packages. Further, Acuros BV will generate high dose rate brachytherapy dose distributions with greater precision than feasible under older systems.
Varian Medical Systems manufactures and sells both medical devices and software for treating cancer and medical conditions associated with radiosurgery and radiotherapy. It is also a leading provider of digital detectors for X-ray imaging in different applications. In addition, the company caters to X-ray imaging requirement for cargo screening and industrial inspection.
We currently have a Neutral rating on Varian.
Read the full analyst report on “VAR”
Zacks Investment Research
